Bryan A. Evans

Array ( [id] => 17467694 [patent_doc_number] => 11274163 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-03-15 [patent_title] => Ultra-stable protein ionic liquids [patent_app_type] => utility [patent_app_number] => 16/587199 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 5247 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467669 [patent_doc_number] => 11274137 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-03-15 [patent_title] => Ultra-stable protein ionic liquids [patent_app_type] => utility [patent_app_number] => 16/587611 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 7661 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17726611 [patent_doc_number] => 11382976 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-07-12 [patent_title] => Ultra-stable protein ionic liquids [patent_app_type] => utility [patent_app_number] => 16/587092 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 6531 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17728818 [patent_doc_number] => 11385201 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-07-12 [patent_title] => Ultra-stable protein ionic liquids [patent_app_type] => utility [patent_app_number] => 16/587124 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 7106 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898475 [patent_doc_number] => 20200148756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER [patent_app_type] => utility [patent_app_number] => 16/579419 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16579419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228823 [patent_doc_number] => 20210355379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => LIGHT-EMITTING PARTICLE [patent_app_type] => utility [patent_app_number] => 17/278263 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15557537 [patent_doc_number] => 20200063180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => PREPARING ANTIBODIES FROM CHO CELL CULTURES FOR CONJUGATION [patent_app_type] => utility [patent_app_number] => 16/573154 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17420173 [patent_doc_number] => 11253603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => Polymer-based macromolecular prodrugs [patent_app_type] => utility [patent_app_number] => 16/969790 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 22 [patent_no_of_words] => 9124 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206558 [patent_doc_number] => 20200239548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/572003 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15740619 [patent_doc_number] => 20200109197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => RECOMBINANT ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/560642 [patent_app_country] => US [patent_app_date] => 2019-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16560642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708779 [patent_doc_number] => 20200101155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS [patent_app_type] => utility [patent_app_number] => 16/560419 [patent_app_country] => US [patent_app_date] => 2019-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16560419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360995 [patent_doc_number] => 20200016262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => Targeting Moiety Peptide Epitope Complexes Having a Plurality of T-Cell Epitopes [patent_app_type] => utility [patent_app_number] => 16/558467 [patent_app_country] => US [patent_app_date] => 2019-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16558467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376370 [patent_doc_number] => 20200325212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => TUMOR-SELECTIVE CTLA-4 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/559561 [patent_app_country] => US [patent_app_date] => 2019-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16559561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105816 [patent_doc_number] => 11958897 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Anti-VAMP2 antibody for inhibiting snare complex and use thereof [patent_app_type] => utility [patent_app_number] => 17/057116 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 5280 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708777 [patent_doc_number] => 20200101154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS [patent_app_type] => utility [patent_app_number] => 16/536154 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16536154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083261 [patent_doc_number] => 20190336441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 16/516411 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060120 [patent_doc_number] => 11104707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof [patent_app_type] => utility [patent_app_number] => 16/515829 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 76134 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345355 [patent_doc_number] => 20200010569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2 [patent_app_type] => utility [patent_app_number] => 16/515231 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17435940 [patent_doc_number] => 11261252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Molecules with specificity for CD79 and CD22 [patent_app_type] => utility [patent_app_number] => 16/513002 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 44637 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 530 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19777430 [patent_doc_number] => 12226451 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => FGF-21 formulations [patent_app_type] => utility [patent_app_number] => 17/257530 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 38128 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257530 [rel_patent_id] =>[rel_patent_doc_number] =>)